SG11202006387QA - Multivalent pneumococcal polysaccharide-protein conjugate composition - Google Patents
Multivalent pneumococcal polysaccharide-protein conjugate compositionInfo
- Publication number
- SG11202006387QA SG11202006387QA SG11202006387QA SG11202006387QA SG11202006387QA SG 11202006387Q A SG11202006387Q A SG 11202006387QA SG 11202006387Q A SG11202006387Q A SG 11202006387QA SG 11202006387Q A SG11202006387Q A SG 11202006387QA SG 11202006387Q A SG11202006387Q A SG 11202006387QA
- Authority
- SG
- Singapore
- Prior art keywords
- protein conjugate
- conjugate composition
- pneumococcal polysaccharide
- multivalent pneumococcal
- multivalent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862626482P | 2018-02-05 | 2018-02-05 | |
| KR20180045246 | 2018-04-18 | ||
| PCT/US2019/016506 WO2019152921A1 (en) | 2018-02-05 | 2019-02-04 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006387QA true SG11202006387QA (en) | 2020-07-29 |
Family
ID=67478950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006387QA SG11202006387QA (en) | 2018-02-05 | 2019-02-04 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11147864B2 (en) |
| EP (1) | EP3749358A4 (en) |
| JP (1) | JP7288451B2 (en) |
| KR (1) | KR20200121822A (en) |
| CN (1) | CN111757754A (en) |
| AU (1) | AU2019215212A1 (en) |
| BR (1) | BR112020014978A2 (en) |
| CA (1) | CA3087572A1 (en) |
| IL (1) | IL276229B2 (en) |
| MX (1) | MX2020007939A (en) |
| PH (1) | PH12020551147A1 (en) |
| SG (1) | SG11202006387QA (en) |
| TW (1) | TWI815860B (en) |
| WO (1) | WO2019152921A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN109890415B (en) | 2016-08-05 | 2023-04-04 | 圣诺菲·帕斯图尔公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CN109862908B (en) | 2016-08-05 | 2023-05-02 | 圣诺菲·帕斯图尔公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| CN117982633A (en) | 2017-12-06 | 2024-05-07 | 默沙东有限责任公司 | Compositions comprising Streptococcus pneumoniae polysaccharide protein conjugates and methods of use thereof |
| JP6950099B2 (en) | 2018-02-05 | 2021-10-13 | サノフィ パスツール インコーポレイティッド | Polyvalent pneumococcal polysaccharide-protein complex composition |
| EP3782642A4 (en) * | 2018-04-18 | 2022-04-13 | SK Bioscience Co., Ltd. | Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof |
| SG11202106541WA (en) | 2018-12-19 | 2021-07-29 | Merck Sharp & Dohme | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| AU2020323498A1 (en) | 2019-07-31 | 2022-03-03 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| US20230183765A1 (en) * | 2020-05-14 | 2023-06-15 | Serum Institute Of India Private Limited | Methods for simultaneous fragmentation and purification of bacterial polysaccharides |
| US20230091255A1 (en) | 2021-09-09 | 2023-03-23 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2153733A1 (en) | 1995-07-12 | 1997-01-13 | Andrew J. Malcolm | Immunogenic oligosaccharide compositions |
| US5866132A (en) | 1995-06-07 | 1999-02-02 | Alberta Research Council | Immunogenic oligosaccharide compositions |
| AU725279B2 (en) | 1995-06-07 | 2000-10-12 | Alberta Research Council Inc. | Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them |
| CA2153730A1 (en) | 1995-07-12 | 1997-01-13 | Andrew J. Malcolm | Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides |
| US5695768A (en) | 1995-06-07 | 1997-12-09 | Alberta Research Council | Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides |
| FR2763244B1 (en) * | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER |
| MY125202A (en) | 1999-03-19 | 2006-07-31 | Smithkline Beecham Biologicals S A | Vaccine |
| FR2806304B1 (en) | 2000-03-17 | 2002-05-10 | Aventis Pasteur | POLYSACCHARIDIC CONJUGATES OF PNEUMOCOCCUS FOR VACCINE USE AGAINST TETANUS AND DIPHTHERIA |
| JP4870895B2 (en) | 2000-06-29 | 2012-02-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Vaccine composition |
| GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| AU2007200116A1 (en) | 2001-04-03 | 2007-02-01 | Glaxosmithkline Biologicals S.A. | Vaccine composition |
| TWI341210B (en) | 2002-04-01 | 2011-05-01 | Glaxosmithkline Biolog Sa | Vaccine kit |
| TWI346555B (en) | 2002-04-01 | 2011-08-11 | Glaxosmithkline Biolog Sa | Vaccine composition |
| BRPI0408094A (en) | 2003-03-13 | 2006-02-14 | Glaxosmithkline Biolog Sa | a process for purifying a bacterial cytolysin, bacterial cytolysin, capsular polysaccharide-bacterial pneumolysin conjugate, immunogenic composition, vaccine, vaccine production process, method of treating or preventing streptococcus pneumoniae infection, and use of pneumolysin or bacterial polysaccharide-pneumolysin |
| US7320874B2 (en) | 2003-07-08 | 2008-01-22 | Aventis Pasteur Sa | Assaying the teichoic acids of gram+ bacteria |
| GB0421083D0 (en) | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
| IL308456A (en) * | 2005-04-08 | 2024-01-01 | Wyeth Llc | Multivalent pneumococcal polysacharide-protein conjugate composition |
| PT1962899E (en) | 2005-12-22 | 2011-10-19 | Glaxosmithkline Biolog Sa | Pneumococcal polysaccharide conjugate vaccine |
| US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
| BRPI0813644B8 (en) | 2007-06-26 | 2021-05-25 | Glaxosmithkline Biologicals Sa | immunogenic composition, vaccine, process to manufacture the same, and use of the immunogenic composition or vaccine |
| BRPI1014494A2 (en) | 2009-04-30 | 2016-08-02 | Coley Pharm Group Inc | pneumococcal vaccine and its uses |
| TW201136603A (en) | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| CN101785857B (en) | 2010-03-05 | 2012-09-26 | 成都安特金生物技术有限公司 | Novel pneumococcal conjugate vaccine and preparation method thereof |
| GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
| CN102068690A (en) | 2010-12-31 | 2011-05-25 | 北京民海生物科技有限公司 | Polyvalent pneumococcal capsular polysaccharide conjugate vaccine and preparation method thereof |
| KR102057217B1 (en) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| IN2015DN00694A (en) | 2012-08-16 | 2015-06-26 | Pfizer | |
| CN103656631B (en) | 2012-09-24 | 2015-08-19 | 北京科兴中维生物技术有限公司 | multivalent pneumococcal capsular polysaccharide-protein conjugate composition and preparation method thereof |
| CN103656632B (en) | 2012-09-24 | 2016-01-13 | 北京科兴中维生物技术有限公司 | Multivalent pneumococcal capsular polysaccharide composition, its preparation method and application |
| KR20140075196A (en) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| ITMI20130142A1 (en) | 2013-01-31 | 2014-08-01 | Biosynth Srl | GLYCOCOUGUGAR VACCINES INCLUDING BASIC UNITS OF AN EXPRIMENT MOLECULAR CONSTRUCTED MULTIPLE EPITHOPES INCORPORATED |
| CN105934251A (en) | 2014-01-21 | 2016-09-07 | 辉瑞大药厂 | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
| PT3096786T (en) | 2014-01-21 | 2021-08-24 | Pfizer | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
| WO2015110941A2 (en) * | 2014-01-21 | 2015-07-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN107029225B (en) | 2014-07-25 | 2020-08-11 | 武汉博沃生物科技有限公司 | Conjugate vaccine and preparation method thereof |
| PT3244917T (en) | 2015-01-15 | 2023-05-31 | Pfizer | Immunogenic compositions for use in pneumococcal vaccines |
| GB201518684D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| EP3377098A1 (en) | 2015-11-20 | 2018-09-26 | Pfizer Inc | Immunogenic compositions for use in pneumococcal vaccines |
| CN106140046B (en) | 2016-07-06 | 2019-02-22 | 江南大学 | Array induction field fluid reaction system and its application |
| CN109890415B (en) | 2016-08-05 | 2023-04-04 | 圣诺菲·帕斯图尔公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CN109862908B (en) | 2016-08-05 | 2023-05-02 | 圣诺菲·帕斯图尔公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CA3037056A1 (en) * | 2016-09-30 | 2018-04-05 | Biological E Limited | Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates |
| JP6950099B2 (en) | 2018-02-05 | 2021-10-13 | サノフィ パスツール インコーポレイティッド | Polyvalent pneumococcal polysaccharide-protein complex composition |
| AU2020323498A1 (en) | 2019-07-31 | 2022-03-03 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
-
2019
- 2019-02-04 SG SG11202006387QA patent/SG11202006387QA/en unknown
- 2019-02-04 JP JP2020541746A patent/JP7288451B2/en active Active
- 2019-02-04 WO PCT/US2019/016506 patent/WO2019152921A1/en active Application Filing
- 2019-02-04 IL IL276229A patent/IL276229B2/en unknown
- 2019-02-04 MX MX2020007939A patent/MX2020007939A/en unknown
- 2019-02-04 EP EP19747393.7A patent/EP3749358A4/en active Pending
- 2019-02-04 BR BR112020014978-0A patent/BR112020014978A2/en unknown
- 2019-02-04 CA CA3087572A patent/CA3087572A1/en active Pending
- 2019-02-04 CN CN201980009513.XA patent/CN111757754A/en active Pending
- 2019-02-04 US US16/966,552 patent/US11147864B2/en active Active
- 2019-02-04 AU AU2019215212A patent/AU2019215212A1/en active Pending
- 2019-02-04 KR KR1020207025714A patent/KR20200121822A/en active Search and Examination
- 2019-02-11 TW TW108104493A patent/TWI815860B/en active
-
2020
- 2020-07-29 PH PH12020551147A patent/PH12020551147A1/en unknown
-
2021
- 2021-10-13 US US17/500,716 patent/US20220031828A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200121822A (en) | 2020-10-26 |
| WO2019152921A1 (en) | 2019-08-08 |
| JP7288451B2 (en) | 2023-06-07 |
| US20220031828A1 (en) | 2022-02-03 |
| CN111757754A (en) | 2020-10-09 |
| AU2019215212A1 (en) | 2020-07-23 |
| JP2021512870A (en) | 2021-05-20 |
| US20200360502A1 (en) | 2020-11-19 |
| TW201945028A (en) | 2019-12-01 |
| EP3749358A1 (en) | 2020-12-16 |
| IL276229A (en) | 2020-09-30 |
| BR112020014978A2 (en) | 2020-12-22 |
| IL276229B2 (en) | 2024-01-01 |
| CA3087572A1 (en) | 2019-08-08 |
| TWI815860B (en) | 2023-09-21 |
| PH12020551147A1 (en) | 2021-05-31 |
| MX2020007939A (en) | 2020-09-03 |
| EP3749358A4 (en) | 2022-04-20 |
| US11147864B2 (en) | 2021-10-19 |
| IL276229B1 (en) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276229B1 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| ZA202202600B (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| IL264552A (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| IL297575B1 (en) | Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates | |
| IL264553A (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| ZA201807203B (en) | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | |
| IL290182A (en) | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same | |
| ZA201708713B (en) | Multivalent pneumococcal conjugate vaccine | |
| EP3668541A4 (en) | Pneumococcal conjugate vaccine formulations | |
| EP3576784A4 (en) | Methods for making polysaccharide-protein conjugates | |
| EP3585803A4 (en) | Pneumococcal conjugate vaccine formulations | |
| EP2932979A4 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| IL281204A (en) | Multivalent pneumococcal vaccines | |
| EP2932980A4 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| IL284349A (en) | Multivalent pneumococcal polysaccharide-protein conjugate vaccine | |
| ZA201708325B (en) | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof | |
| ZA201901969B (en) | A composition of multivalent pneumococcal capsular polysaccharide-carrier protein conjugates and use thereof | |
| SG11201911757WA (en) | Novel multivalent polysaccharide - protein conjugate vaccine composition and formulation thereof | |
| IL279855A (en) | Improvements in immunogenic conjugates | |
| ZA202103644B (en) | Multivalent glycoconjugates immunogenic compositions | |
| AU2013360597B2 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition |